LOH

Affini-T Therapeutics to Present Data From Its Preclinical Programs Targeting KRAS G12D and TP53 R175H at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Retrieved on: 
Wednesday, May 1, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Cancer, HLA, MD, Cell, Data, Patient, TP53, Gene, Society, LOH, MHC, LVV, Annual general meeting, TCR, Therapy, Vaccine

Affini-T Therapeutics, Inc. , a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that data from its preclinical gene edited HLA-A*11:01 KRAS G12D (AFNT-212) and HLA-A*02:01 TP53 R175H T Cell Receptor (TCR) T cell therapy products for the treatment of solid cancers will be presented at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting held in Baltimore, MD May 7-11.

Key Points: 
  • Affini-T Therapeutics, Inc. , a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that data from its preclinical gene edited HLA-A*11:01 KRAS G12D (AFNT-212) and HLA-A*02:01 TP53 R175H T Cell Receptor (TCR) T cell therapy products for the treatment of solid cancers will be presented at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting held in Baltimore, MD May 7-11.
  • “Our mission is to address the significant unmet needs of patients with hard-to-treat solid tumors by advancing precision immunotherapies that target oncogenic driver mutations,” said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics.
  • “We believe that our non-viral targeted knock-in platform, THRIVETM, will enable us to cost-effectively engineer safe and effective T cell therapy products.
  • “TCR based therapies targeting cancer driver mutations recognize the human leukocyte antigen (HLA)/peptide complex on tumor cells,” said Dirk Nagorsen, M.D., Chief Medical Officer at Affini-T Therapeutics.

A2 Bio to Highlight Progress of CAR T Clinical Programs in Three Poster Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, April 24, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, CEA, ASCO, LOH, HLA, Carcinoembryonic antigen, MSLN, Patient, Society, Vaccine

A2 Biotherapeutics, Inc. (A2 Bio) a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells, today announced the acceptance of three posters for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting May 31-June 4, 2024, in Chicago, Ill. A2 Bio will present two Trials in Progress on its first-in-human Phase 1/2 studies EVEREST-1 and EVEREST-2, and one poster highlighting the BASECAMP-1 master prescreening study protocol’s impact on increasing trial diversity.

Key Points: 
  • A2 Biotherapeutics, Inc. (A2 Bio) a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells, today announced the acceptance of three posters for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting May 31-June 4, 2024, in Chicago, Ill. A2 Bio will present two Trials in Progress on its first-in-human Phase 1/2 studies EVEREST-1 and EVEREST-2, and one poster highlighting the BASECAMP-1 master prescreening study protocol’s impact on increasing trial diversity.
  • EVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH)
    EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH)
    Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH)

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Retrieved on: 
Monday, April 8, 2024
ACT, Gene, Biotechnology, Acceleration, LOH, CDX, Risk, Patient, NGS, Biomarker, Research, MSI, DNA, Cancer, Spacecraft, AACR, MRD, Recurrence, FDA, Health, Plasma, Neoplasm, Medicine, Pharmaceutical industry

BURLINGTON, N.C., April 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision oncology portfolio, solidifying its commitment to advancing cancer research and patient care on a global scale. The announcement underscores Labcorp's dedication to investing in scientific, diagnostic and laboratory innovations to support its pharmaceutical, biotechnology and clinical research partners in bringing groundbreaking therapies to market.

Key Points: 
  • The announcement underscores Labcorp's dedication to investing in scientific, diagnostic and laboratory innovations to support its pharmaceutical, biotechnology and clinical research partners in bringing groundbreaking therapies to market.
  • "Our portfolio expansion enhances our integrated services to empower our partners with the solutions and support they need to advance their development programs and make a lasting difference in patients' lives."
  • Labcorp recently announced the commercial availability of Labcorp Plasma Detect, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) MRD solution for research and investigational use.
  • Labcorp's deep scientific expertise and comprehensive solutions include specialized pre-clinical discovery, biomarker and companion diagnostics (CDx) development and post-commercialization capabilities.

Lepidico Ltd Announces Participation in 121 Mining Investment Conference in Cape Town

Retrieved on: 
Monday, January 15, 2024
Lithium, ASX, LOH, Conference, Mining, Rubidium

Perth, Australia--(Newsfile Corp. - January 15, 2024) - Lepidico Ltd (ASX: LPD), an Australian ASX listed Lithium and Critical Minerals development company is pleased to advise that the company will be attending the 121 Cape Town Investment Conference in February 2024.

Key Points: 
  • Perth, Australia--(Newsfile Corp. - January 15, 2024) - Lepidico Ltd (ASX: LPD), an Australian ASX listed Lithium and Critical Minerals development company is pleased to advise that the company will be attending the 121 Cape Town Investment Conference in February 2024.
  • Lepidico has a well-developed sustainability strategy designed to meet the most stringent lender and customer requirements at the company's stage of development.
  • The Managing Director of Lepidico Ltd, Mr Joe Walsh is attending the 121 Conference.
  • Please go to the 121 Conference website: https://www.weare121.com/ for further information and to arrange meetings.

FDA Grants Breakthrough Device Designation To Tempus’ HLA-LOH Companion Diagnostic Test

Retrieved on: 
Tuesday, August 15, 2023
Technology, Medical Devices, FDA, Health Technology, Other Health, Biotechnology, General Health, Health, Oncology, Artificial Intelligence, LOH, Diagnosis, Cancer, CDX, Intelligence, Safety, Patient, HLA, Biomarker, Doctor of Philosophy, Medicine, Medical imaging, Tempus

Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its HLA-LOH assay as a companion diagnostic (CDx) test.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its HLA-LOH assay as a companion diagnostic (CDx) test.
  • The test uses a machine learning model to analyze sequence data produced by Tempus’ FDA-approved, next generation sequencing-based xT CDx assay.
  • “HLA-LOH provides a clear molecular distinction between cancer and non-cancer cells and is a potential biomarker for immune therapy resistance.
  • “This Breakthrough Device Designation from the FDA recognizes the novelty and potential clinical impact of our HLA-LOH test for this promising biomarker.

Caris Life Sciences Introduces the Caris Assure™ Liquid Biopsy Assay at ASCO 2022

Retrieved on: 
Friday, June 3, 2022
Loss of heterozygosity, Exome, Indeterminate, Research, Society, Liquid biopsy, Transcriptome, Neoplasm, MBA, Weld quality assurance, Plague, Artificial intelligence, CHIP, RNA, TMB, CEO, Disease, ASCO, CFRNA, WES, Blood, Annual general meeting, Gene, Physician, MSI, Nucleic acid thermodynamics, American Society of Clinical Oncology, Patient, DNA, American Securities, Microsatellite instability, Diagnosis, Twitter, WTS, Industry, Drug development, LOH, Cancer, Protein, Medical imaging, Dentistry, Medical device

CHICAGO, June 3, 2022 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today introduced its Caris Assure™ liquid biopsy assay at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Booth #22081).

Key Points: 
  • Caris Assure is the most powerful liquid biopsy assay ever developed, providing whole exome and whole transcriptome sequencing (WES/WTS) assessing somatic tumor, somatic CHIP and germline alterations
    CHICAGO, June 3, 2022 /PRNewswire/ -- Caris Life Sciences (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today introduced its Caris Assure liquid biopsy assay at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Booth #22081).
  • "Caris Assure establishes a new standard for liquid biopsy testing," said David D. Halbert , Chairman, Founder and CEO of Caris Life Sciences.
  • With Caris Assure, we have created the most extensive sequencing assay available to ensure we leave no stone unturned in properly guiding treatment selection and ongoing cancer care management."
  • This unique assay includes characterization of somatic tumor alterations, somatic Clonal Hematopoiesis of Indeterminate Potential (CHIP) alterations and identification of incidental germline findings.

Lucence Showcases Promising Data on ctDNA and ctRNA Liquid Biopsy Assay for Lung Cancer at 2022 ASCO Annual Meeting

Retrieved on: 
Tuesday, May 31, 2022
Research, Medical Devices, Hospitals, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, DNA, NGS, Gene, Doctor of Philosophy, Patient, MBBS, Health, Lung cancer, Society, PARP, BRAF, Circulating tumor DNA, Tyrosine, CtRNA, Plasma, MET, RNA, Liquid biopsy, ASCO, Large-cell lung carcinoma, NRG1, CLIA, LOH, Mutation, HRD, Chowdhury, Medical imaging, NSCLC, Neoplasm

Lucence strives to provide clinicians with the most clinically actionable information to impact patient care using liquid biopsy.

Key Points: 
  • Lucence strives to provide clinicians with the most clinically actionable information to impact patient care using liquid biopsy.
  • The data we are presenting at 2022 ASCO shows how a total nucleic acid approach combining ctDNA and ctRNA in one liquid biopsy assay could dramatically increase actionable molecular information in lung cancer patients, said Min-Han Tan, PhD, MBBS, Founding CEO of Lucence.
  • In plasma samples from non-small cell lung cancer (NSCLC) patients that were either baseline driver-negative (by ctDNA) or treated with tyrosine kinase-inhibitors, the combined assay found 8.7% (9/103) more actionable fusions than ctDNA alone.
  • The data support combining ctRNA with ctDNA in liquid biopsy to increase the total actionable diagnostic information in NSCLC patients where tissue samples are lacking, especially for gene fusions not amenable to detection in ctDNA.

Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene

Retrieved on: 
Tuesday, April 12, 2022
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, LOH, Allele, Head, Cancer, U.S. Securities and Exchange Commission, HNSCC, College of American Pathologists, PSNL, Twitter, College, Genomics, DASH, Immunotherapy, MD, Nature Communications, Cervical cancer, PD-L1, Leadership, Machine learning, PCR, Patient, Form S-3, LinkedIn, Efficiency, SVP, NSCLC, Form, Nasdaq, Immune system, Method, CD274, HLA, Deletion, Clinical Laboratory Improvement Amendments, Medical imaging, Chief Justice of Hungary

Human leukocyte antigen loss of heterozygosity (HLA LOH) allows cancer cells to escape immune recognition by deleting HLA alleles, causing the suppressed presentation of tumor neoantigens.

Key Points: 
  • Human leukocyte antigen loss of heterozygosity (HLA LOH) allows cancer cells to escape immune recognition by deleting HLA alleles, causing the suppressed presentation of tumor neoantigens.
  • Despite its importance in immunotherapy response, few methods exist to detect HLA LOH, and their accuracy is not well understood.
  • Further, detecting HLA LOH accurately from sequencing data is of interest given the growing ubiquity of tumor molecular profiling.
  • The Personalis study details the development of DASH (Deletion of Allele-Specific HLAs), a novel machine learning-based algorithm to detect HLA LOH from paired tumor-normal sequencing data.

Bionano Genomics Announces Release of Version 6.2 of its NxClinical Software with Significant New Capabilities for Cancer Research Applications Including HRD Analysis

Retrieved on: 
Thursday, April 7, 2022
Adoption, Company, Private Securities Litigation Reform Act, SNV, Cell, Friends, Biomarker, Poly (ADP-ribose) polymerase, Genome, Informatics, Autism, PARP, Agilent Technologies, Genomics, DNA, Hospital Insurance and Diagnostic Services Act, HR, Lineagen, Automation, Forward-looking statement, HRD, Research, NGS, Doctor of Philosophy, Neoplasm, Cancer, Medicine, Health, U.S. Securities and Exchange Commission, LST, Software, Industry, Biology, Lists of publishing companies, TAI, COVID-19, OGM, GLOBE, Friends of Cancer Research, Â, Solution, SAN, LOH, Annual report, Patient, Security (finance), Medical imaging, Antibiotics

Integrated HRD genomic scarring has been introduced into this latest version of NxClinical software, developed by BioDiscovery, to measure genomic instability in a platform-agnostic way.

Key Points: 
  • Integrated HRD genomic scarring has been introduced into this latest version of NxClinical software, developed by BioDiscovery, to measure genomic instability in a platform-agnostic way.
  • Diagnostic Laboratory Services (Hawaii) will serve as the collaborator and laboratory testing site, leveraging the HRD measurement capabilities of NxClinical software.
  • We believe NxClinical 6.2 software offers an unparalleled visualization of the consequences of HRD and can streamline HRD analysis across different platforms and clinical research settings.
  • Once we have successfully integrated OGM data capabilities into NxClinical software, we expect structural variants uniquely identified by OGM to enhance the performance of our HRD analysis capabilities.

DGAP-News: SYNLAB AG: SYNLAB partners with OncoDNA to provide comprehensive biomarker testing for cancer therapy selection in Germany

Retrieved on: 
Friday, April 1, 2022
TMB, Microsatellite instability, Immunotherapy, OncoDNA, IHC, Genetics, HRD, Head, Pathology, Cancer, Precision medicine, CEO, Lists of diseases, HER2/neu, Oncology, Biomarker, Gene, LOH, Patient, MSI, Immunohistochemistry, Partnership, Medical imaging

SYNLAB, Europe's leading medical diagnostics services provider, and OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases, announce a partnership to provide oncologists with the high-quality, pan-cancer OncoDEEP(R) biomarker test in Germany.

Key Points: 
  • SYNLAB, Europe's leading medical diagnostics services provider, and OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases, announce a partnership to provide oncologists with the high-quality, pan-cancer OncoDEEP(R) biomarker test in Germany.
  • The comprehensive test helps to predict patient responses to a wide range of approved and experimental cancer therapies, further expanding SYNLAB's offering in personalised diagnostics and precision medicine in the field of oncology.
  • In certain cancer types, such as HER2-positive breast cancer, immunohistochemistry (IHC) analyses will also be performed to measure protein expression and reveal patients eligibility to anti-cancer drugs.
  • This collaboration will further support the uptake of precision medicine across Germany."